Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Dostarlimab in Untreated pMMR/MSS Resectable Colon Cancer
NCT06830239Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of dostarlimab in colon cancer, sponsored by UZ Leuven. Started Apr 2025; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06830239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830239.